XPS™ to be delivered to the first clinic in France

Hôpital FOCH in Paris is the first clinic in France that has decided to use
XPS™. Delivery and installation of XPS™ is estimated to take place at the end of
March 2016.
The clinic in Paris has more than 25 years’ experience of lung transplantation
and is one of the leading lung transplant clinics in France, with a well-reputed
Ex Vivo Lung Perfusion (EVLP) program.

Under the leadership of Professor Alain Chapelier, the clinic in Paris has
carried out EVLP using the so-called manual STEEN Solution™ method. “We will now
be able to continue to explore EVLP using XPS™ and STEEN Solution™,” says Dr
Edouard Sage, who is in charge of the clinical EVLP program.

XPS™ is the only CE-marked and FDA approved integrated system on the market
today which gives the user the flexibility to perform evaluation of lungs before
transplantation through a standardized and simplified procedure. Use of XPS™ has
shown good clinical results at 18 clinics in the US, many of which are national
leaders in their field. Six XPS™ contracts have now been signed by European
clinics, giving them access to the XPS™ system for lung transplantation, and the
company notes continuing high interest for the XPS™ in Europe.

“We are delighted that the FOCH clinic in Paris, which has great experience of
transplanting lungs after performing EVLP with STEEN Solution™ with good
clinical results, is now moving on to a more standardized and simplified EVLP
using the XPS™ system,” says Magnus Nilsson, CEO of XVIVO Perfusion.

February 24, 2016
Gothenburg
XVIVO Perfusion AB (publ)
For further information please contact:
Christoffer Rosenblad, CFO, +1 720 616 2101,
christoffer.rosenblad@xvivoperfusion.com
Magnus Nilsson, CEO, +46 31 788 2150, magnus.nilsson@xvivoperfusion.com
For further information on XVIVO Perfusion’s business, please refer to the
company’s website, www.xvivoperfusion.com

The information was submitted for publication on February 24, 2016 at 8:30 a.m.

This is a translation of the Swedish version of the press release. When in
doubt, the Swedish wording prevails.
________________________________________________________________________________
_ 
_____________________________________

XVIVO Perfusion AB is a medical technology company which develops solutions and
systems for assessing and preserving organs outside the body and for selecting
usable organs and maintaining them in optimal condition pending transplantation.
The company is headquartered in Gothenburg, Sweden, and has one office in the
USA. The XVIVO share is listed on NASDAQ First North premier and has the ticker
symbol XVIVO. More information can be found on the website
www.xvivoperfusion.com. The Certified Adviser is Redeye, www.redeye.se.
________________________________________________________________________________
_ 
_____________________________________

XVIVO Perfusion AB (publ), Box 53015, SE-400 14 Göteborg. Corporate identity
number 556561-0424.
Tel: 46 31 788 21 50. Fax: 46 31 788 21 69.
E-mail: info@xvivoperfusion.com. Website: www.xvivoperfusion.com